Claim passport · AB-BPC157-US-001

What the evidence for BPC-157 actually shows.

BPC-157 is widely promoted online, but promotion, preclinical findings, and established human clinical evidence are not interchangeable.

Jurisdiction United StatesLast source check September 18, 2026Version 1.0Review state Editorially reviewed; clinical review pending

Bounded claim

BPC-157 is not an FDA-approved drug, and available evidence does not establish the broad human treatment claims commonly made in online promotion.

What is established

  • The FDA lists BPC-157 among bulk drug substances that may present significant safety risks in compounding.
  • FDA materials identify limited safety-related information and potential immunogenicity or impurity concerns.
  • Online availability does not establish approval, identity, sterility, safety, or effectiveness.

What remains uncertain

  • Clinical effectiveness for the broad injury, gut, recovery, or wellness claims used in promotion.
  • The identity and quality of products sold outside regulated drug supply channels.
  • Long-term safety, appropriate use, and patient-specific risk.

Source trail

Review and limitations

Editorial review: AminoBrief publishing team, source and scope check completed September 18, 2026. Qualified clinical reviewer: not yet assigned. This page is therefore educational and must not be relied upon for diagnosis, treatment, dosing, sourcing, or product verification.

Correction history: none. Report a correction.